FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a monoclonal antibody or its antigen-binding fragment that specifically binds human XI factor and human Xia factor, a method for its producing, as well as to a composition containing the specified antibody or its fragment and a kit. Polynucleotide encoding the specified monoclonal antibody or its antigen-binding fragment, as well as a vector containing it and a host cell are also disclosed.
EFFECT: invention is effective for the treatment or prevention of thrombotic disorders or thrombotic complications, as well as for the treatment or prevention of thromboembolic disorders or thromboembolic complications.
20 cl, 11 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
